Status:

COMPLETED

5 Versus 10 Units of Insulin in Hyperkalemia Management

Lead Sponsor:

Oman Medical Speciality Board

Collaborating Sponsors:

Sultan Qaboos University

Conditions:

Hyperkalemia

Potassium Imbalance

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The goal of this study is to compare 5 units of intravenous Regular insulin to 10 units of intravenous regular insulin in the management of hyperkalemia. We will measure the efficacy of these 2 doses ...

Detailed Description

Introduction: Hyperkalaemia is a serum Potassium (K) level of more than 5.5 mEq/L. It is a common emergency medicine presentation and can be life-threatening. Because of the emergency in correcting hy...

Eligibility Criteria

Inclusion

  • Hyperkalemia patients with lab potassium levels equal to or more than 5.5 mEq/L (≥ 5.5 mEq/L)+.
  • Adult: age 18 years or more.
  • Agreed to participate in the study.
  • If an investigator decides to start anti-hyperkalemia medications based on the VBG/ABG patient can be enrolled but if the main laboratory value is less than 5.5 mEq/L patients will be excluded

Exclusion

  • Cardiac arrest
  • Hyperglycemia with random blood sugar 20 mmol/L (13) or with acute diabetic complications like Diabetic Ketoacidosis / Hyperosmolar Hyperglycemic State.
  • Hypoglycemia with random blood sugar (RBS) ≤ 3.89 mmol/l in Diabetic patients and less than 3 mmol/l in non-diabetic patients.
  • Allergies for any medication in the protocol.
  • Pregnancy.
  • Hemolyzed potassium level as reported by the main lab.
  • Hemolysis, Tumor lysis syndrome, or Rhabdomyolysis due to the ongoing release of potassium.
  • Acidosis with a pH less than 7.1 will require Sodium bicarbonate (NaHO3).
  • A patient who will need urgent Furosemide (Lasix), and or dialysis during the study period of 2 hours.
  • Refused to participate.

Key Trial Info

Start Date :

October 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2025

Estimated Enrollment :

384 Patients enrolled

Trial Details

Trial ID

NCT06036823

Start Date

October 1 2023

End Date

September 30 2025

Last Update

December 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sultan Qaboos University hospital

Seeb, Muḩāfaz̧at Masqaţ, Oman, 123